正在加载公司
Just reported
From Humacyte's results release of 2026年11月10日; its quarterly report has since been filed.
Actual
US$1M
+37% y/y
+153% q/q
Guided
—
No guide given
Actual
-US$0.06
Guided
—
No guide given
Actual
-US$23.5M
Guided
—
No guide given
Q4 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Humacyte is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$47.5BA+
EXELExelixis, Inc.US$17BA+
JAZZJazz Pharmaceuticals plcUS$15.4BA
HALOHalozyme Therapeutics, Inc.US$11.5BA+
TECHBIO-Techne CorpUS$11.4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A基于 Humacyte, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
公司指引：2026 财年第 4 季度营收 约 US$800K — 同比增长 71.3%
Grade C-
价格下方的色带显示每个日期的评级，仅依据当时已公开的文件计算。
显示 Humacyte, Inc. 评级历史 4 个季度中的 2 个。 其余 2 个可回溯到 2026年3月。
